Drug Safety

, Volume 23, Issue 6, pp 483–507 | Cite as

Immunological Principles of Adverse Drug Reactions

The Initiation and Propagation of Immune Responses Elicited by Drug Treatment
  • Dean J. Naisbitt
  • S. Fraser Gordon
  • Munir Pirmohamed
  • B. Kevin Park
Review Article

Abstract

Adverse drug reactions account for between 2 to 5% of all hospital admissions and can prevent the administration of an otherwise effective therapeutic agent. Hypersensitivity or immune-mediated reactions, although less common, tend to be proportionately more serious. There is convincing evidence to implicate the immune system in the pathogenesis of hypersensitivity reactions. Our understanding of the way in which the immune system recognises drugs is based on the hapten hypothesis; the onset of hypersensitivity involves drug bioactivation, covalent binding to proteins, followed by uptake, antigen processing and T cell proliferation. Central to this hypothesis is the critical role of drug metabolism, with the balance between metabolic bioactivation and detoxification being one important component of individual susceptibility.

The purpose of this review is to classify drug hypersensitivity reactions in terms of their clinical presentation, and also to consider recent advances in our understanding of the chemical, biochemical and, in particular, cellular immunological mechanisms of hypersensitivity. The following topics are reviewed: (i) drug disposition and cellular metabolism; (ii) mechanisms of antigen processing and presentation; (iii) the role of cytokines and co-stimulatory molecules in the induction and maintenance of a polarised immune response; and (iv) the application of the hapten hypothesis, danger hypothesis and serial triggering model to drug hypersensitivity. Agreater understanding of the mechanism(s) of hypersensitivity may identify novel therapeutic strategies and help to combat one of the more severe forms of adverse reactions to drugs.

Notes

Acknowledgments

The authors would like to express thanks to Miss C. Dodd for her help in the production of this manuscript. Thanks are also extended to Dr C. Burkhart and Professor W.J. Pichler for their constructive criticism. D.J. Naisbitt holds a Wellcome Trust Research Career Development Fellowship. S.F. Gordon is a PhD student funded by AVERT. B.K. Park is a Wellcome Principal Fellow.

References

  1. 1.
    Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–40PubMedGoogle Scholar
  2. 2.
    Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29–34PubMedGoogle Scholar
  3. 3.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5PubMedGoogle Scholar
  4. 4.
    Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277: 307–11PubMedGoogle Scholar
  5. 5.
    Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969–88PubMedGoogle Scholar
  6. 6.
    Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68: 385–424PubMedGoogle Scholar
  7. 7.
    Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295–8PubMedGoogle Scholar
  8. 8.
    Gleichmann E. Mechanisms of autoantibody formation and chemically-induced autoimmunity. Immunol Today 1989; 10: S30–1PubMedGoogle Scholar
  9. 9.
    Cribb AE, Lee BL, Trepanier LA, et al. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15: 9–50PubMedGoogle Scholar
  10. 10.
    Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39: S8–16PubMedGoogle Scholar
  11. 11.
    Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994; 11: 196–212PubMedGoogle Scholar
  12. 12.
    Hess DA, Rieder MJ. The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 1997; 31: 1378–87PubMedGoogle Scholar
  13. 13.
    Meyboom RHB, Lindquist M, Egberts ACG. An ABC of drug-related problems. Drug Saf 2000; 22: 415–23PubMedGoogle Scholar
  14. 14.
    Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, editor. Clinical aspects of immunology. Oxford: Oxford University Press, 1968: 575–96Google Scholar
  15. 15.
    Batchelor FR, Dewdney JM, Gazzard D. Penicillin allergy: the formation of the penicilloyl determinant. Nature 1965; 206: 362–4PubMedGoogle Scholar
  16. 16.
    Christie G, Coleman JW, Park BK. Drug-protein conjugates—XVII. The effect of storage on the antigenicity and immunogenicity of benzylpenicillin in the rat. Biochem Pharmacol 1988; 37: 4121–8PubMedGoogle Scholar
  17. 17.
    Lafaye P, Lapresle C. Fixation of penicilloyl groups to albumin and appearance of anti-penicilloyl antibodies in penicillintreated patients. J Clin Invest 1988; 82: 7–12PubMedGoogle Scholar
  18. 18.
    Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 155: 2670–8PubMedGoogle Scholar
  19. 19.
    Ahlstedt S, Ekstrom B, Svard PO, et al. New aspects on antigens in penicillin allergy. Crit Rev Toxicol 1980; 7: 219–77PubMedGoogle Scholar
  20. 20.
    Padovan E. T-cell response in penicillin allergy. Clin Exp Allergy 1998; 28: 33–6PubMedGoogle Scholar
  21. 21.
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85PubMedGoogle Scholar
  22. 22.
    Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev 1990; 22: 87–144PubMedGoogle Scholar
  23. 23.
    Kao J, Carver MP. Cutaneous metabolism of xenobiotics. Drug Metab Rev 1990; 22: 363–410PubMedGoogle Scholar
  24. 24.
    Merk HF, Hertl M. Immunologic mechanisms of cutaneous drug reactions. Semin Cutan Med Surg 1996; 15: 228–35PubMedGoogle Scholar
  25. 25.
    Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377–95PubMedGoogle Scholar
  26. 26.
    Freeman TM. Anaphylaxis: diagnosis and treatment. Prim Care 1998; 25: 809–17PubMedGoogle Scholar
  27. 27.
    Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988; 18: 515–40PubMedGoogle Scholar
  28. 28.
    Casolaro V, Georas SN, Song Z, et al. Biology and genetics of atopic disease. Curr Opin Immunol 1996; 8: 796–803PubMedGoogle Scholar
  29. 29.
    Vincent PC. Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs 1986; 31: 52–63Google Scholar
  30. 30.
    Pisciotta AV. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226–37PubMedGoogle Scholar
  31. 31.
    Ammus S, Yunis AA. Drug-induced red cell dyscrasias. Blood Rev 1989; 3: 71–82PubMedGoogle Scholar
  32. 32.
    Petz LD, Fundenberg HH. Coombs-positive hemolytic anemia caused by penicillin administration. N Engl J Med 1966; 274: 171–8PubMedGoogle Scholar
  33. 33.
    Levine B, Redmond A. Immunochemical mechanisms of penicillin induced immune haemolytic anaemia in man. Int Arch Allergy Appl Immunol 1967; 21: 594–606Google Scholar
  34. 34.
    Bougie D, Johnson ST, Weitekamp LA, et al. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 1997; 90: 407–13PubMedGoogle Scholar
  35. 35.
    Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299–366PubMedGoogle Scholar
  36. 36.
    Madison FW, Squier TL. The etiology of primary granulocytopenia (agranulocytic angina). JAMA 1934; 102: 755–9Google Scholar
  37. 37.
    Rhodes EG, Ball J, Franklin IM. Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br Med J Clin Res Ed 1986; 292: 717–8PubMedGoogle Scholar
  38. 38.
    Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 1990; 336: 785–7PubMedGoogle Scholar
  39. 39.
    Barrett AJ, Weller E, Rozengurt N, et al. Amidopyrine agranulocytosis: drug inhibition of granulocyte colonies in the presence of patient’s serum. BMJ 1976; 2: 850–1PubMedGoogle Scholar
  40. 40.
    Clarke JB, Neftel K, Kitteringham NR, et al. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95: 369–75PubMedGoogle Scholar
  41. 41.
    Stricker BH, Barendregt JN, Claas FH. Thrombocytopenia and leucopenia with mianserin-dependent antibodies. Br J Clin Pharmacol 1985; 19: 102–4PubMedGoogle Scholar
  42. 42.
    Alvir JMJ, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States Experience. J Clin Psychopharmacol 1994; 14: 87–9PubMedGoogle Scholar
  43. 43.
    Williams DP, Pirmohamed M, Naisbitt DJ, et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997; 283: 1375–82PubMedGoogle Scholar
  44. 44.
    Williams DP, Pirmohamed M, Naisbitt DJ, et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207–16PubMedGoogle Scholar
  45. 45.
    Jaunkalns R, Shear NH, Sokoluk B, et al. Antimyeloperoxidase antibodies and adverse reactions to clozapine. Lancet 1992; 339: 1611–2PubMedGoogle Scholar
  46. 46.
    Guest I, Sokoluk B, MacCrimmon J, et al. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998; 131: 53–65PubMedGoogle Scholar
  47. 47.
    Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67: 84–99PubMedGoogle Scholar
  48. 48.
    National halothane study. Summary of the National Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA 1966; 197: 775–88Google Scholar
  49. 49.
    Kenna JG, Neuberger J, Williams R. An enzyme-linked immunosorbent assay for detection of antibodies against halothanealtered hepatocyte antigens. J Immunol Methods 1984; 75: 3–14PubMedGoogle Scholar
  50. 50.
    Homberg JC, Abuaf N, Helmy-Khalil S, et al. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 1985; 5: 722–7PubMedGoogle Scholar
  51. 51.
    Uzunalimogu B, Yardley JH, Boitnott JK. The liver in mild halothane hepatitis. Light and electron microscopic findings with special reference to the mononuclear cell infiltrate. Am J Pathol 1970; 61: 457–78Google Scholar
  52. 52.
    Furst SM, Luedke D, Gaw HH, et al. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol Appl Pharmacol 1997; 143: 245–55PubMedGoogle Scholar
  53. 53.
    Furst SM, Gandolfi AJ. Interaction of lymphocytes with Kupffer cells from halothane-exposed guinea pigs. Int Arch Allergy Immunol 1997; 114: 46–53PubMedGoogle Scholar
  54. 54.
    Zimmerman HJ, Lewis JH, Ishak KG, et al. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984; 4: 315–23PubMedGoogle Scholar
  55. 55.
    Breen EG, McNicholl J, Cosgrove E, et al. Fatal hepatitis associated with diclofenac. Gut 1986; 27: 1390–3PubMedGoogle Scholar
  56. 56.
    Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38: 744–51PubMedGoogle Scholar
  57. 57.
    Pumford NR, Myers TG, Davila JC, et al. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol 1993; 6: 147–50PubMedGoogle Scholar
  58. 58.
    Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 1995; 22: 213–22PubMedGoogle Scholar
  59. 59.
    Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four italian regions. Br J Clin Pharmacol 1999; 48: 839–46PubMedGoogle Scholar
  60. 60.
    Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358–63PubMedGoogle Scholar
  61. 61.
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7PubMedGoogle Scholar
  62. 62.
    Sachs B, Ronnau AC, von Schmiedeberg S, et al. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195: 60–4PubMedGoogle Scholar
  63. 63.
    Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190–4PubMedGoogle Scholar
  64. 64.
    Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466–8PubMedGoogle Scholar
  65. 65.
    Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598–604PubMedGoogle Scholar
  66. 66.
    Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462–72PubMedGoogle Scholar
  67. 67.
    Schnyder B, Frutig K, Mauri-Hellweg D, et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28: 1412–7PubMedGoogle Scholar
  68. 68.
    Guengerich FP. Enzymatic oxidation of xenobiotic chemicals. Crit Rev Biochem Mol Biol 1990; 25: 97–153PubMedGoogle Scholar
  69. 69.
    Stricker BHC, Spoelstra P, editors. Drug-induced hepatic injury: a comprehensive survey of the literature on adverse drug reactions up to January 1985. Amsterdam: Elsevier, 1985Google Scholar
  70. 70.
    Kao J, Carver MP. Cutaneous metabolism of xenobiotics. Drug Metab Rev 1990; 22: 363–410PubMedGoogle Scholar
  71. 71.
    Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994; 11: 114–44PubMedGoogle Scholar
  72. 72.
    Wynn RL, Meiller TF. CYP enzymes and adverse drug reactions. Gen Dent 1998; 46: 436–8PubMedGoogle Scholar
  73. 73.
    Gonzalez FJ. The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption. Toxicol Lett 1998; 102-103: 161–6PubMedGoogle Scholar
  74. 74.
    Tingle MD, Jewell H, Maggs JL, et al. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol 1995; 50: 1113–9PubMedGoogle Scholar
  75. 75.
    Maggs JL, Williams D, Pirmohamed M, et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 1995; 275: 1463–75PubMedGoogle Scholar
  76. 76.
    Uetrecht JP, Ma HM, MacKnight E, et al. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem Res Toxicol 1995; 8: 226–33PubMedGoogle Scholar
  77. 77.
    Maggs JL, Tingle MD, Kitteringham NR, et al. Drug-protein conjugates—XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem Pharmacol 1988; 37: 303–11PubMedGoogle Scholar
  78. 78.
    Lambert C, Park BK, Kitteringham NR. Activation of mianserin and its metabolites by human liver microsomes. Biochem Pharmacol 1989; 38: 2853–8PubMedGoogle Scholar
  79. 79.
    Feierman DE, Melnikov Z. Cytochrome P-4502E1-dependent formation of trifluoroacetyl adducts from halothane by transduced HepG2 cells. Alcohol Clin Exp Res 1997; 21: 1606–11PubMedGoogle Scholar
  80. 80.
    Lopez Garcia MP, Dansette PM, Valadon P, et al. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-4502C9 and 2C10. Eur J Biochem 1993; 213: 223–32PubMedGoogle Scholar
  81. 81.
    Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996; 24: 469–79PubMedGoogle Scholar
  82. 82.
    Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 1996; 24: 509–14PubMedGoogle Scholar
  83. 83.
    Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722–7PubMedGoogle Scholar
  84. 84.
    Munns AJ, De Voss JJ, Hooper WD, et al. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 1997; 10: 1049–58PubMedGoogle Scholar
  85. 85.
    Cribb AE, Nuss CE, Alberts DW, et al. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996; 9: 500–7PubMedGoogle Scholar
  86. 86.
    Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126: 1393–407PubMedGoogle Scholar
  87. 87.
    Mills BJ, Lang CA. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol 1996; 52: 401–6PubMedGoogle Scholar
  88. 88.
    Brockmoller J, Cascorbi I, Kerb R, et al. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 1998; 102-103: 173–83PubMedGoogle Scholar
  89. 89.
    de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36: 439–52PubMedGoogle Scholar
  90. 90.
    Salinas AE, Wong MG. Glutathione S-transferases: a review. Curr Med Chem 1999; 6: 279–309PubMedGoogle Scholar
  91. 91.
    Uetrecht JP. Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes. Pharm Res 1989; 6: 265–73PubMedGoogle Scholar
  92. 92.
    Pirmohamed M, Kitteringham NR, Park BK. Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. Pharmacol Ther 1992; 53: 105–25PubMedGoogle Scholar
  93. 93.
    Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994; 11: 196–212PubMedGoogle Scholar
  94. 94.
    Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1995-96; 65–97Google Scholar
  95. 95.
    Pirmohamed M, Park BK. Drug reactions in HIV-infected patients. Postgraduate doctor 1995; 18: 438–44Google Scholar
  96. 96.
    Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643–56PubMedGoogle Scholar
  97. 97.
    Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 1997; 17: 89–118PubMedGoogle Scholar
  98. 98.
    Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999; 103: 192–9PubMedGoogle Scholar
  99. 99.
    Jensen PE. Mechanisms of antigen presentation. Clin Chem Lab Med 1999; 37: 179–86PubMedGoogle Scholar
  100. 100.
    Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996; 80: 225–35PubMedGoogle Scholar
  101. 101.
    Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133–41PubMedGoogle Scholar
  102. 102.
    Kalish RS. Antigen processing: the gateway to the immune response. J Am Acad Dermatol 1995; 32: 640–52PubMedGoogle Scholar
  103. 103.
    Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581–90PubMedGoogle Scholar
  104. 104.
    Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg 1996; 15: 217–27PubMedGoogle Scholar
  105. 105.
    Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology 1997; 119: 37–43PubMedGoogle Scholar
  106. 106.
    Ware JA, Graf ML, Martin BM, et al. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: possible role in allergic reactions. Chem Res Toxicol 1998; 11: 164–71PubMedGoogle Scholar
  107. 107.
    Hertl M, Jugert F, Merk HF. CD8+ dermal T cells froma sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215–20PubMedGoogle Scholar
  108. 108.
    Merk HF, Baron J, Hertl M, et al. Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds. Int Arch Allergy Immunol 1997; 113: 173–6PubMedGoogle Scholar
  109. 109.
    Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the ‘danger hypothesis’ and innate immune system. Chem Res Toxicol 1999; 12: 387–95PubMedGoogle Scholar
  110. 110.
    Steinman RM, Inaba K, Turley S, et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 1999; 60: 562–7PubMedGoogle Scholar
  111. 111.
    Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 1999; 20: 302–6PubMedGoogle Scholar
  112. 112.
    Vasseur F, Le Campion A, Pavlovitch JH. Distribution of cycling T lymphocytes in blood and lymphoid organs during immune responses. J Immunol 1999; 162: 5164–72PubMedGoogle Scholar
  113. 113.
    Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100: 136–41PubMedGoogle Scholar
  114. 114.
    Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human ap T lymphocytes. J Clin Invest 1998; 102: 1591–8PubMedGoogle Scholar
  115. 115.
    Pichler WJ, Schnyder B, Zanni MP, et al. Role of Tcells in drug allergies. Allergy 1998; 53: 225–32PubMedGoogle Scholar
  116. 116.
    von Greyerz S, Zanni MP, Frutig K, et al. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. Immunology 1999; 162: 595–602Google Scholar
  117. 117.
    Doherty PC. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1996. Cell mediated immunity in virus infections. Scand J Immunol 1997; 46: 527–40PubMedGoogle Scholar
  118. 118.
    Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19: 395–404PubMedGoogle Scholar
  119. 119.
    Meuer SC, Schlossman SF, Reinherz EL. Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci USA 1982; 79: 4395–9PubMedGoogle Scholar
  120. 120.
    Bjorkman PJ, Saper MA, Samraoui B, et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512–8PubMedGoogle Scholar
  121. 121.
    Jensen PE. Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Biopolymers 1997; 43: 303–22PubMedGoogle Scholar
  122. 122.
    Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998; 16: 323–58PubMedGoogle Scholar
  123. 123.
    Saito T, Watanabe N. Positive and negative thymocyte selection. Crit Rev Immunol 1998; 18: 359–70PubMedGoogle Scholar
  124. 124.
    Matzinger P. Why positive selection? Immunol Rev 1993; 135: 81–117PubMedGoogle Scholar
  125. 125.
    Hilkens CM, Snijders A, Snijdewint FG, et al. Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur Respir J 1996; 22 Suppl.: 90–4Google Scholar
  126. 126.
    Gesbert F, Delespine-Carmagnat M, Bertoglio P. Recent advances in the understanding of interleukin-2 signal transduction. J Immunol 1998; 18: 307–20Google Scholar
  127. 127.
    Pender MP. Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Immunol Cell Biol 1999; 77: 216–23PubMedGoogle Scholar
  128. 128.
    Sweetser MT, Morrison LA, Braciale VL, et al. Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature 1989; 342: 180–2PubMedGoogle Scholar
  129. 129.
    Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255: 1261–3PubMedGoogle Scholar
  130. 130.
    von Schmiedeberg S, Hanten U, Goebel C, et al. T cells ignore the parent drug propylthiouracil but are sensitized to a reactive metabolite generated in vivo. Clin Immunol Immunopathol 1996; 80: 162–70Google Scholar
  131. 131.
    Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today 1992; 13: 179–84PubMedGoogle Scholar
  132. 132.
    Ghosh P, Amaya M, Mellins E, et al. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995; 378: 457–62PubMedGoogle Scholar
  133. 133.
    Geuze HJ. The role of endosomes and lysosomes in MHC class II functioning. Immunol Today 1998; 19: 282–7PubMedGoogle Scholar
  134. 134.
    Green JM, Pierce SK. Class II antigen processing compartments and the function of HLA-DM. Int Rev Immunol 1996; 13: 209–19PubMedGoogle Scholar
  135. 135.
    Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994; 368: 554–8PubMedGoogle Scholar
  136. 136.
    Vogt AB, Kropshofer H, Hammerling GJ. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Hum Immunol 1997; 54: 170–9PubMedGoogle Scholar
  137. 137.
    Cresswell P, Bangia N, Dick T, et al. The nature of the MHC class I peptide loading complex. Immunol Rev 1999; 172: 21–8PubMedGoogle Scholar
  138. 138.
    Abele R, Tampe R. Function of the transport complex TAP in cellular immune recognition. Biochim Biophys Acta 1999; 1461: 405–19PubMedGoogle Scholar
  139. 139.
    Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389–418PubMedGoogle Scholar
  140. 140.
    Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11: 203–10PubMedGoogle Scholar
  141. 141.
    Chambers CA, Krummel MF, Boitel B, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 1996; 153: 27–46PubMedGoogle Scholar
  142. 142.
    Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791–6PubMedGoogle Scholar
  143. 143.
    Guinan EC, Gribben JG, Boussiotis VA, et al. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261–82PubMedGoogle Scholar
  144. 144.
    Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995; 2: 555–9PubMedGoogle Scholar
  145. 145.
    Byrne JA, Butler JL, Reinherz EL, et al. Virgin and memory T cells have different requirements for activation via the CD2 molecule. Int Immunol 1989; 1: 29–35PubMedGoogle Scholar
  146. 146.
    Bowen MA, Lee RK, Miragliotta G, et al. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 1996; 156: 442–9PubMedGoogle Scholar
  147. 147.
    Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862–4PubMedGoogle Scholar
  148. 148.
    Vink A, Uyttenhove C, Wauters P, et al. Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor. Eur J Immunol 1990; 20: 1–6PubMedGoogle Scholar
  149. 149.
    Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235–53PubMedGoogle Scholar
  150. 150.
    Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol 1996; 157: 3280–9PubMedGoogle Scholar
  151. 151.
    Parra E, Varga M, Hedlund G, et al. Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding. Mol Cell Biol 1997; 17: 1314–23PubMedGoogle Scholar
  152. 152.
    Huber B, Devinsky O, Gershon RK, et al. Cell-mediated immunity: delayed-type hypersensitivity and cytotoxic responses are mediated by different T-cell subclasses. J Exp Med 1976; 143: 1534–9PubMedGoogle Scholar
  153. 153.
    Lederman S, Suciu-Foca N. Antigen presenting cells integrate opposing signals from CD4+ and CD8+ regulatory T lymphocytes to arbitrate the outcomes of immune responses. Hum Immunol 1999; 60: 533–61PubMedGoogle Scholar
  154. 154.
    Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348–57PubMedGoogle Scholar
  155. 155.
    Dutton RW. The regulation of the development of CD8 effector T cells. J Immunol 1996; 157: 4287–92PubMedGoogle Scholar
  156. 156.
    Cerwenka A, Carter LL, Reome JB, et al. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J Immunol 1998; 161: 97–105PubMedGoogle Scholar
  157. 157.
    Kerdine S, Lebrec H, Bertoglio J, et al. Interleukin-4 plays a dominant role in Th1- or Th2-like responses during the primary immune response to the hapten penicillin. Mol Immunol 1996; 33: 71–7PubMedGoogle Scholar
  158. 158.
    Biddison WE, Cruikshank WW, Center DM, et al. CD8+myelin peptide-specific T cells can chemoattract CD4+ myelin peptide-specific T cells: importance of IFN-inducible protein 10. J Immunol 1998; 160: 444–8PubMedGoogle Scholar
  159. 159.
    Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480–3PubMedGoogle Scholar
  160. 160.
    Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–8PubMedGoogle Scholar
  161. 161.
    Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999; 5: 285–94PubMedGoogle Scholar
  162. 162.
    Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 147–61PubMedGoogle Scholar
  163. 163.
    Bendelac A, Schwartz RH. Th0 cells in the thymus: the question of T-helper lineages. Immunol Rev 1991; 123: 169–88PubMedGoogle Scholar
  164. 164.
    Grewe M, Bruijnzeel-Koomen CA, Schopf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19: 359–61PubMedGoogle Scholar
  165. 165.
    Kapsenberg ML, Hilkens CM, Wierenga EA, et al. The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy 1999; 29: 33–6PubMedGoogle Scholar
  166. 166.
    Annunziato F, Manetti R, Tomasevic I, et al. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production. FASEB J 1996; 10: 769–76PubMedGoogle Scholar
  167. 167.
    Avice MN, Sarfati M, Triebel F, et al. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol 1999; 162: 2748–53PubMedGoogle Scholar
  168. 168.
    Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457–70PubMedGoogle Scholar
  169. 169.
    Carter LL, Dutton RW. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J Immunol 1995; 155: 1028–31PubMedGoogle Scholar
  170. 170.
    Mosmann TR, Li L, Sad S. Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin Immunol 1997; 9: 87–92PubMedGoogle Scholar
  171. 171.
    Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271–9PubMedGoogle Scholar
  172. 172.
    Seder RA, Le Gros GG. The functional role of CD8+ T helper type 2 cells. J Exp Med 1995; 181: 5–7PubMedGoogle Scholar
  173. 173.
    O’Garra A, Hosken N, Macatonia S, et al. The role of macrophage-and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995; 146: 466–72PubMedGoogle Scholar
  174. 174.
    Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297–322PubMedGoogle Scholar
  175. 175.
    Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707–18PubMedGoogle Scholar
  176. 176.
    Murphy KM. T lymphocyte differentiation in the periphery. Curr Opin Immunol 1998; 10: 226–32PubMedGoogle Scholar
  177. 177.
    Kapsenberg ML, Hilkens CM, Wierenga EA, et al. The role of antigen-presenting cells in the regulation of allergen-specific T cell responses. Curr Opin Immunol 1998; 10: 607–13PubMedGoogle Scholar
  178. 178.
    Abe N, Katamura K, Shintaku N, et al. Prostaglandin E2 and IL-4 provide naive CD4+ T cells with distinct inhibitory signals for the priming of IFN-gamma production. Cell Immunol 1997; 181: 86–92PubMedGoogle Scholar
  179. 179.
    O’Garra A, Murphy K. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 1994; 6: 458–66PubMedGoogle Scholar
  180. 180.
    Delespesse G, Yang LP, Ohshima Y, et al. Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2 effectors. Vaccine 1998; 16: 1415–9PubMedGoogle Scholar
  181. 181.
    D’Andrea A, Aste-Amezaga M, Valiante NM, et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–8PubMedGoogle Scholar
  182. 182.
    Cavani A, Mei D, Guerra E, et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol 1998; 111: 621–8PubMedGoogle Scholar
  183. 183.
    Short S, Merkel BJ, Caffrey R, et al. Defective antigen processing correlates with a low level of intracellular glutathione. Eur J Immunol 1996; 26: 3015–20PubMedGoogle Scholar
  184. 184.
    Peterson JD, Herzenberg LA, Vasquez K, et al. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 1998; 95: 3071–6PubMedGoogle Scholar
  185. 185.
    Eck HP, Gmunder H, Hartmann M, et al. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler 1989; 370: 101–8PubMedGoogle Scholar
  186. 186.
    Staal FJ, Ela SW, Roederer M, et al. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992; 339: 909–12PubMedGoogle Scholar
  187. 187.
    Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999 162: 3256–62PubMedGoogle Scholar
  188. 188.
    Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991–1045PubMedGoogle Scholar
  189. 189.
    Cai ZA, Brunmark MR, Jackson D, et al. Transfected Drosophilia cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci USA 1996; 93: 14736–43PubMedGoogle Scholar
  190. 190.
    Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399–415PubMedGoogle Scholar
  191. 191.
    Santoro MG. Heat shock factors and the control of the stress response. Biochem Pharmacol 2000; 59: 55–63PubMedGoogle Scholar
  192. 192.
    van Eden W, van der Zee R, Taams LS, et al. Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response. Immunol Rev 1998; 164: 169–74PubMedGoogle Scholar
  193. 193.
    Koopmans PP, Burger DM. Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Pharm World Sci 1998; 20: 253–7PubMedGoogle Scholar
  194. 194.
    Matsuo F. Lamotrigine. Epilepsia 1999; Suppl. 5: 30–6Google Scholar
  195. 195.
    Furst SM, Luedke D, Gaw HH, et al. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol Appl Pharmacol 1997; 143: 245–55PubMedGoogle Scholar
  196. 196.
    Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115–22PubMedGoogle Scholar
  197. 197.
    Hanahan D, Christofori G, Naik P, et al. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32: 2386–93Google Scholar
  198. 198.
    Speiser DE, Miranda R, Zakarian A, et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645–53PubMedGoogle Scholar
  199. 199.
    Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: Endogenous activators of dendritic cells. Nature Med 1999; 5: 1249–55PubMedGoogle Scholar
  200. 200.
    Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immuno-stimulatory dendritic cells. J Exp Med 2000; 191: 423–34PubMedGoogle Scholar
  201. 201.
    Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000; 405: 85–90PubMedGoogle Scholar
  202. 202.
    Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998; 134: 1108–12PubMedGoogle Scholar
  203. 203.
    Tohyama M, Yahata Y, Yasukawa M, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998; 134: 1113–7PubMedGoogle Scholar
  204. 204.
    Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5: 1237–57PubMedGoogle Scholar
  205. 205.
    Tshachler E, Bergstresser PR, Stingl G. HIV related skin diseases. Lancet 1996; 348: 659–63Google Scholar
  206. 206.
    Cribb AE, Spielberg SP. Sulfamethoxazole is metabolised to a hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522–6PubMedGoogle Scholar
  207. 207.
    Mitra AK, Thummel KE, Kalhorn TF, et al. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 1996; 59: 332–40PubMedGoogle Scholar
  208. 208.
    Gill HJ, Hough SJ, Naisbitt DJ, et al. The relationship between the disposition and the immunogenicity of sulphamethoxazole in the rat. J Pharmacol Exp Ther 1997; 282: 1375–82Google Scholar
  209. 209.
    Daftarian MP, Filion MP, Cameron W, et al. Immune response to sulphamethoxazole in patients with AIDS. Clin Diagnostic Lab Immunol 1995; 2: 199–204Google Scholar
  210. 210.
    Meekins CV, Sulivan TJ, Gruchalla RS. Immunological analysis of sulphonamide drug allergy: identification of sulphamethoxazole substituted human serum proteins. J Allergy Clin Immunol 1994; 94: 1017–24PubMedGoogle Scholar
  211. 211.
    Adkinson NF. Beta-lactam crossreactivity. Clin Exp Allergy 1998; 28: 37–40PubMedGoogle Scholar
  212. 212.
    Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164: 6647–54PubMedGoogle Scholar
  213. 213.
    Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; I(8178): 1107–9Google Scholar
  214. 214.
    McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000; 18: 505–8PubMedGoogle Scholar
  215. 215.
    Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487–95PubMedGoogle Scholar
  216. 216.
    Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999; 26: 718–22PubMedGoogle Scholar
  217. 217.
    Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Dean J. Naisbitt
    • 1
  • S. Fraser Gordon
    • 1
  • Munir Pirmohamed
    • 1
  • B. Kevin Park
    • 1
  1. 1.Department of Pharmacology and TherapeuticsUniversity of LiverpoolLiverpool, MerseysideEngland

Personalised recommendations